Salama Ali
In 2017, North America signified the major share in the biomarker market. The Asia Pacific verified the highest growth from 2017 to 2022 for the biomarker advances to market. Factors such as the growing rate of malignancy, the development of the geriatric population and the support of private and public links for biomarker research are driving the development of this regional section. By influencing advance, the biomarker breakthrough market is categorized by immunoassays, PCR, mass spectrometry, NGS, chromatography, cytogenetic and other different advances. The immunoassay percentage accounted for most of it in 2017. This section is additionally categorized into ELISA, western blot and protein microarrays. In 2017, the ELISA fragment exemplified the major share in the immunoassay market.
English 
Spanish 
Chinese 
Russian 
French 
Japanese 
Portuguese 
Hindi